NCT02050932View on ClinicalTrials.gov

The Optimization of Iron Bioavailability of Supplements Using Hepcidin Levels in Humans

NACompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions
Iron Deficiency
Interventions
DIETARY_SUPPLEMENT

60 mg Fe as FeSO4 with stable isotopic labels

Subjects will receive FeSo4 supplements labeled with stable isotopic labels (54Fe, 57Fe, 58Fe) and iron absorption will be measured for each administration

Trial Locations (1)

8092

ETH Zürich, Laboratory of Human Nutrition, Zurich

All Listed Sponsors
lead

Swiss Federal Institute of Technology

OTHER

NCT02050932 - The Optimization of Iron Bioavailability of Supplements Using Hepcidin Levels in Humans | Biotech Hunter | Biotech Hunter